Compare T Rowe Price Group Inc (TROW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T Rowe Price Group Inc vs Twist Bioscience Corp — how do they compare? T Rowe Price Group Inc trades at $107.71 (market cap $23.34B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: T Rowe Price Group Inc is far larger — about 2.8× Twist Bioscience Corp's market cap, and T Rowe Price Group Inc pays a 4.75% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TROW | TWST | |
|---|---|---|
Market Cap | $23.34B | $8.42B |
Sector | Financials | Health |
52-Week High | $121.68 | $153.10 |
52-Week Low | $86.19 | $24.16 |
Enterprise Value | $20.54B | $8.35B |
Dividend Yield | 4.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T. Rowe Price (TROW) trades at $109.42, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.99, net income margin of 29.26%, and consistent dividend payments. Recent developments include the acquisition of F/m Investments to expand fixed-income ETF capabilities and significant AI adoption across operations. Revenue has grown from $6.5B in 2022 to $7.3B in 2025, with net income reaching $2.09B.
TROW presents a mixed outlook with attractive valuation metrics and solid profitability offset by bearish technical indicators and equity outflows. The consensus price target of $112.50 suggests modest upside potential. Key risks include market-sensitive revenue streams and competitive pressures in asset management. Institutional buying from firms like BlackRock provides support, but investors should weigh the strong fundamentals against near-term technical weakness.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
